BR112016027089A2 - método para monomerização de agregado de matriz metaloproteinase 7 (mmp-7) - Google Patents

método para monomerização de agregado de matriz metaloproteinase 7 (mmp-7)

Info

Publication number
BR112016027089A2
BR112016027089A2 BR112016027089A BR112016027089A BR112016027089A2 BR 112016027089 A2 BR112016027089 A2 BR 112016027089A2 BR 112016027089 A BR112016027089 A BR 112016027089A BR 112016027089 A BR112016027089 A BR 112016027089A BR 112016027089 A2 BR112016027089 A2 BR 112016027089A2
Authority
BR
Brazil
Prior art keywords
mmp
monomerization
buffer solution
aggregate
aggregates
Prior art date
Application number
BR112016027089A
Other languages
English (en)
Other versions
BR112016027089B1 (pt
Inventor
Takeo Hideki
Nakatake Hiroshi
Hirashima Masaki
MATSUYAMA Reiko
Morikawa Wataru
Original Assignee
The Chemo Sero Therapeutic Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chemo Sero Therapeutic Res Institute filed Critical The Chemo Sero Therapeutic Res Institute
Publication of BR112016027089A2 publication Critical patent/BR112016027089A2/pt
Publication of BR112016027089B1 publication Critical patent/BR112016027089B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24023—Matrilysin (3.4.24.23)

Abstract

um método para monomerização de agregados de mmp-7 é provido. um método para monomerização de agregados de mmp-7 compreendendo o tratamento de agregados de mmp-7 com uma solução tampão compreendendo um cloreto de cátion monovalente (cloreto de sódio, cloreto de potássio, etc.) em uma baixa concentração ou com uma solução tampão não compreendendo um cloreto de cátion monovalente, um método para preparação de mmp-7 que envolve o dito método para monomerização, e uma composição (farmacêutica) compreendendo mmp-7 na solução tampão mencionada anteriormente. no caso onde uma composição (farmacêutica) compreendendo mmp-7 em uma baixa concentração é preparada, a solução tampão mencionada anteriormente compreendendo álcoois de açúcares ou açúcares, é usada.
BR112016027089-4A 2014-05-21 2015-05-20 Método para monomerização de agregados de matriz metaloproteinase 7 (mmp-7), composição farmacêutica compreendendo mmp-7 e seu uso para tratamento de deslocamento de disco intervertebral e processo para preparação de mmp-7 BR112016027089B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014105452 2014-05-21
JP2014-105452 2014-05-21
PCT/JP2015/064451 WO2015178414A1 (ja) 2014-05-21 2015-05-20 マトリックスメタロプロテアーゼ７（ｍｍｐ－７）会合体の単量体化方法

Publications (2)

Publication Number Publication Date
BR112016027089A2 true BR112016027089A2 (pt) 2017-10-17
BR112016027089B1 BR112016027089B1 (pt) 2023-08-29

Family

ID=

Also Published As

Publication number Publication date
AU2015262415A1 (en) 2016-12-01
WO2015178414A1 (ja) 2015-11-26
US20200140843A1 (en) 2020-05-07
EP3147358A4 (en) 2017-12-06
CA2949238A1 (en) 2015-11-26
RU2724543C2 (ru) 2020-06-23
MX2016015187A (es) 2017-07-27
US10774321B2 (en) 2020-09-15
CN106536731A (zh) 2017-03-22
TWI743023B (zh) 2021-10-21
JPWO2015178414A1 (ja) 2017-04-20
RU2016150091A (ru) 2018-06-22
KR20170003665A (ko) 2017-01-09
CA2949238C (en) 2023-05-02
EP3147358A1 (en) 2017-03-29
JP6755793B2 (ja) 2020-09-16
TW201625788A (zh) 2016-07-16
KR102286557B1 (ko) 2021-08-04
AU2015262415B2 (en) 2021-04-01
RU2016150091A3 (pt) 2019-01-24
US20170081654A1 (en) 2017-03-23
MX2021001285A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
BR112017014049A2 (pt) método para reduzir a perda de circulação em uma formação subterrânea, fluido de tratamento e sistema para obstrução de uma zona de perda de circulação
BR112017023478A2 (pt) Melhoramento do efeito das células t car- concebidas por meio de vacinação de ácido nucleico
BR102014015634A8 (pt) Método implementado por computador para evitar ataques contra sistemas de autorização, programa de computador, e produto de programa de computador
BR112016024903A2 (pt) métodos e composição para formular materiais de circulação perdida
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
BR112018011984A2 (pt) instrumento para expansão palatal
BR112015028031A2 (pt) pedra, barragem para controle de cheias e método para a sua construção
BR112016002421A2 (pt) métodos e sistema para utilização de fluidos de tratamento de acidificação complexantes, e, fluido de tratamento de acidificação complexante
BR112017000199A2 (pt) composição adjuvante que compreende cloreto de colina ou fosfato de potássio (dibásico como um inibidor de hidratação)
BR112018009241A8 (pt) dispositivo criptográfico disposto de modo a computar uma cifra de bloco-alvo em uma mensagem de entrada, método criptográfico para computar uma cifra de bloco-alvo em uma mensagem de entrada, programa de computador e mídia legível por computador
BR112016015851A2 (pt) Formulações farmacêuticas estabilizadas de insulina aspart
BR112016014756A8 (pt) formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso
BR112017006925A2 (pt) composições e kits para tratamento de prurido e métodos de uso das mesmas
BR112017010218A2 (pt) placa de gesso.
BR112017004925A2 (pt) composição e método
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
BR112015032326A2 (pt) composições de fibra inorgânicas
BR112016012838A2 (pt) Composição para a administração oral de um agente bioativo incluindo partículas que compreendem um agente bioativo e um polímero mucoadesivo em uma solução aquosa, e, método de preparação da composição
BR112015017688A2 (pt) elemento de vedação reforçado com fibra
BR112018005881A2 (pt) método e particulado de tratamento
BR112018004619A2 (pt) vidro de segurança e método para a obtenção
PT10925T (pt) Dioptro configurado para restringir as radiações electromagnéticas que danificam o sistema visual
BR112017016875A2 (pt) método, composição e sistema para produzir um fluido de furo de poço.
BR112019004413A2 (pt) método para criar um padrão em um material natural de origem humana ou animal, material natural de origem humana ou animal, e, uso de um material natural.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25G Requested change of headquarter approved

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP)

Free format text: ANULADA A PUBLICACAO CODIGO 25.7 NA RPI NO 2570 DE 07/04/2020 POR TER SIDO INDEVIDA.

B25G Requested change of headquarter approved

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: KM BIOLOGICS CO., LTD. (JP)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/05/2015, OBSERVADAS AS CONDICOES LEGAIS